Three versus six months adjuvant oxaliplatin-based chemotherapy for patients with stage III colon cancer: The French participation to the International Duration Evaluation of Adjuvant chemotherapy (IDEA) project.

被引：1
|
作者：
Andre, Thierry
Bonnetain, Franck
Mineur, Laurent
Bennouna, Jaafar
Desrame, Jerome
Faroux, Roger
Dauba, Jerome
Vernerey, Dewi
Aissat, Nasredine
Louvet, Christophe
Lepere, Celine
Dupuis, Olivier Jean Marie
Becouarn, Yves
Mabro, May
Egreteau, Joelle
Bouche, Olivier
Deplanque, Gael
Ychou, Marc
De Gramont, Aimery
Taieb, Julien
机构：
[1] Hop St Antoine, APHP, Dept Med Oncol, Paris, France
[2] Univ Hosp Besancon, Dept Oncol, Methodol & Qual Life Unit, INSERM,UMR 1098, Besancon, France
[3] French Natl Platform Qual Life & Canc, Besancon, France
[4] Inst St Catherine, Avignon, France
[5] Inst Cancerol Ouest, Nantes, France
[6] Hop Prive Jean Mermoz, Lyon, France
[7] Ctr Hosp Dept Oudairies, La Roche Sur Yon, France
[8] Hop Layne, Dept Gastroenterol, Mt De Marsan, France
[9] CHRU Besancon, Methodol & Qual Life Oncol Unit, Besancon, France
[10] GERCOR, Paris, France
[11] Inst Mutualiste Montsouris, Paris, France
[12] Hop Europeen Georges Pompidou, Paris, France
[13] Clin Victor Hugo, Le Mans, France
[14] Inst Bergonie, Bordeaux, France
[15] Hop Foch, Suresnes, France
[16] Ctr Hosp Bretagne Sud, Lorient, France
[17] CHU Robert Debre, Reims, France
[18] CHU Vaudois, Med Oncol, Lausanne, Switzerland
[19] Inst Reg Canc Montpellier, Montpellier, France
[20] Franco British Inst, Levallois Perret, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.3500
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3500
引用
收藏
页数：5
相关论文
共 50 条
  • [1] Three versus six months adjuvant oxaliplatin plus fluoropyrimidine chemotherapy for patients with stage III colon cancer: The Hellenic Oncology Research Group (HORG) participation to the International Duration Evaluation of Adjuvant (IDEA) chemotherapy project.
    Souglakos, John
    Boukovinas, Ioannis
    Xynogalos, Spyros
    Kakolyris, Stylianos
    Ziras, Nikolaos
    Vaslamatzis, Michael
    Ardavanis, Alexandros
    Athanasiadis, Athanasios
    Androulakis, Nikolaos E. M.
    Kentepozidis, Nikolaos K.
    Christopoulou, Athina
    Makrantonakis, Paris
    Varthalitis, Ioannis I.
    Christofyllakis, Charalampos
    Emmanouilides, Christos E.
    Mavroudis, Dimitrios
    Prinarakis, Efthimios
    Kalisperi, Aggeliki
    Hatzidaki, Dora
    Georgoulias, Vassilis
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [2] Three versus six months adjuvant FOLFOX or CAPOX for high risk stage II and stage III colon cancer patients: The efficacy results of Hellenic Oncology Research Group (HORG) participation to the International Duration Evaluation of Adjuvant chemotherapy (IDEA) project.
    Sougklakos, Ioannis
    Boukovinas, Ioannis
    Xynogalos, Spyros
    Kakolyris, Stylianos
    Ziras, Nikolaos
    Vaslamatzis, Michael
    Athanasiadis, Athanasios
    Ardavanis, Alexandros
    Androulakis, Nikolaos E. M.
    Christopoulou, Athina
    Makrantonakis, Paris
    Bompolaki, Iliada
    Christofyllakis, Charalampos
    Kentepozidis, Nikolaos K.
    Emmanouilides, Christos E.
    Kouroussis, Charalambos
    Prinarakis, Efthimios
    Kalisperi, Ageliki
    Mavroudis, Dimitrios
    Georgoulias, Vassilis
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [3] Efficacy of 3 versus 6 months of oxaliplatin-based adjuvant chemotherapy for stage III colon cancer (CC): Results from phase III ACHIEVE trial as part of the International Duration Evaluation of Adjuvant therapy (IDEA) Collaboration
    Yoshino, T.
    Yamanaka, T.
    Kotaka, M.
    Manaka, D.
    Eto, T.
    Hasegawa, J.
    Takagane, A.
    Nakamura, M.
    Kato, T.
    Munemoto, Y.
    Nakamura, F.
    Bando, H.
    Taniguchi, H.
    Gamoh, M.
    Shiozawa, M.
    Sakamoto, J.
    Saji, S.
    Mizushima, T.
    Ohtsu, A.
    Mori, M.
    ANNALS OF ONCOLOGY, 2017, 28
  • [4] The prospective French participitation to IDEA (International Duration Evaluation of Adjuvant Chemotherapy) study in stage III colon cancer: Patients' characteristics and safety analysis of 3 versus 6 months of adjuvant chemotherapy.
    Andre, Thierry
    De Gramont, Aimery
    Mineur, Laurent
    Desrame, Jerome
    Faroux, Roger
    Bennouna, Jaafar
    Dauba, Jerome
    Louvet, Christophe
    Pernot, Simon
    Dupuis, Olivier Jean Marie
    Becouarn, Yves
    Mabro, May
    Egreteau, Joelle
    Bouche, Olivier
    Bonnetain, Franck
    de larauze, Marine Hug
    Le Malicot, Karine
    Taieb, Julien
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [5] Effect of Delay in Adjuvant Oxaliplatin-Based Chemotherapy for Stage III Colon Cancer
    Peixoto, Renata D'Alpino
    Kumar, Aalok
    Speers, Caroline
    Renouf, Daniel
    Kennecke, Hagen F.
    Lim, Howard J.
    Cheung, Winson Y.
    Melosky, Barbara
    Gill, Sharlene
    CLINICAL COLORECTAL CANCER, 2015, 14 (01) : 25 - 30
  • [6] Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): The IDEA (International Duration Evaluation of Adjuvant chemotherapy) collaboration
    Shi, Qian
    Sobrero, Alberto F.
    Shields, Anthony Frank
    Yoshino, Takayuki
    Paul, James
    Taieb, Julien
    Sougklakos, Ioannis
    Kerr, Rachel
    Labianca, Roberto
    Meyerhardt, Jeffrey A.
    Bonnetain, Franck
    Watanabe, Toshiaki
    Boukovinas, Ioannis
    Renfro, Lindsay A.
    Grothey, Axel
    Niedzwiecki, Donna
    Torri, Valter
    Andre, Thierry
    Sargent, Daniel J.
    Iveson, Timothy
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [7] Three Versus 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Patients With Stage III Colon Cancer: Disease-Free Survival Results From a Randomized, Open-Label, International Duration Evaluation of Adjuvant (IDEA) France, Phase III Trial
    Andre, Thierry
    Vernerey, Dewi
    Mineur, Laurent
    Bennouna, Jaafar
    Desrame, Jerome
    Faroux, Roger
    Fratte, Serge
    de Larauze, Marine Hug
    Paget-Bailly, Sophie
    Chibaudel, Benoist
    Bez, Jeremie
    Dauba, Jerome
    Louvet, Christophe
    Lepere, Celine
    Dupuis, Olivier
    Becouarn, Yves
    Mabro, May
    Egreteau, Joelle
    Bouche, Olivier
    Deplanque, Gael
    Ychou, Marc
    Galais, Marie Pierre
    Ghiringhelli, Francois
    Dourthe, Louis Marie
    Bachet, Jean-Baptiste
    Khalil, Ahmed
    Bonnetain, Franck
    de Gramont, Aimery
    Taieb, Julien
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15) : 1469 - +
  • [8] Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): Updated results of IDEA (International Duration Evaluation of Adjuvant chemotherapy)
    Grothey, A.
    Sobrero, A.
    Meyerhardt, J. A.
    Yoshino, T.
    Paul, J.
    Taieb, J.
    Souglakos, I.
    Kerr, R.
    Labianca, R.
    Shields, A. F.
    Bonnetain, F.
    Yamanaka, T.
    Boukovinas, I.
    Shi, Q.
    Meyers, J. P.
    Niedzwiecki, D.
    Torri, V.
    Sargent, D. J.
    Andre, T.
    Iveson, T.
    ANNALS OF ONCOLOGY, 2017, 28
  • [9] Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): The IDEA (International Duration Evaluation of Adjuvant chemotherapy) collaboration.
    Shi, Qian
    Sobrero, Alberto F.
    Shields, Anthony Frank
    Yoshino, Takayuki
    Paul, James
    Taieb, Julien
    Sougklakos, Ioannis
    Kerr, Rachel
    Labianca, Roberto
    Meyerhardt, Jeffrey A.
    Bonnetain, Franck
    Watanabe, Toshiaki
    Boukovinas, Ioannis
    Renfro, Lindsay A.
    Grothey, Axel
    Niedzwiecki, Donna
    Torri, Valter
    Andre, Thierry
    Sargent, Daniel J.
    Iveson, Timothy
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (18)
  • [10] The Greek participitation to IDEA (International Duration Evaluation of Adjuvant Chemotherapy) study of 3 versus 6 months of adjuvant chemotherapy in stage III colon cancer: Patients' characteristics and safety analysis.
    Souglakos, John
    Boukovinas, Ioannis
    Kakolyris, Stylianos
    Ziras, Nikolaos
    Androulakis, Nikolaos E. M.
    Ardavanis, Alexandros
    Kentepozidis, Nikolaos K.
    Vaslamatzis, Michael
    Athanasiadis, Athanasios
    Christopoulou, Athina
    Makrantonakis, Paris
    Polyzos, Aristidis
    Mavroudis, Dimitrios
    Mala, Anastasia
    Kalisperi, Aggeliki
    Xynogalos, Spyros
    Varthalitis, Ioannis I.
    Kouroussis, Charalambos
    Prinarakis, Efthimios
    Georgoulias, Vassilis
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
12345